DeepMed Research

Jiangsu Alphamab Biopharmaceuticals Co.,Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Phase 1

Not yet recruiting

Conditions: Inoperable Locally Advanced HER2-Negative Breast Cancer
Metastatic HER2-Negative Breast Cancer

Interventions: Drug: JSKN016
Drug: Paclitaxel (albumin bound)
Drug: Eribulin
Drug: Capecitabine
Drug: Pembrolizumab

First Posted Date: 2025-04-24

Last Posted Date: 2025-04-30

Lead Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Target Recruit Count: 180

Registration Number: NCT06942234

Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

Phase 1

Not yet recruiting

Conditions: Advanced Non-small Cell Lung Cancer

Interventions: Drug: JSKN016
Drug: Carboplatin
Drug: Furmonertinib Mesylate
Drug: Ivonescimab
Drug: Docetaxel
Drug: Tislelizumab
Drug: Pembrolizumab

First Posted Date: 2025-03-11

Last Posted Date: 2025-03-11

Lead Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Target Recruit Count: 288

Registration Number: NCT06868732

Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study

Phase 2

Not yet recruiting

Conditions: Advanced Non-small Cell Lung Cancer

Interventions: Drug: JSKN016
Drug: Docetaxel

First Posted Date: 2025-01-15

Last Posted Date: 2025-01-15

Lead Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Target Recruit Count: 220

Registration Number: NCT06775483

JSKN033 in Chinese Subjects with Advanced Malignant Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Malignant Tumors

Interventions: Drug: JSKN033

First Posted Date: 2025-01-13

Last Posted Date: 2025-01-13

Lead Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Target Recruit Count: 430

Registration Number: NCT06770881

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

Phase 3

Not yet recruiting

Conditions: Ovarian Cancer
Primary Peritoneal
Fallopian Tube Cancers

Interventions: Drug: JSKN003
Drug: Doxorubicin
Drug: Paclitaxel
Drug: Topotecan

First Posted Date: 2024-12-30

Last Posted Date: 2024-12-31

Lead Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Target Recruit Count: 430

Registration Number: NCT06751485

To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Malignant Solid Tumor

Interventions: Drug: JSKN016 injection

First Posted Date: 2024-09-12

Last Posted Date: 2024-09-12

Lead Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Target Recruit Count: 140

Registration Number: NCT06592417

JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: JSKN033 Injection

First Posted Date: 2024-01-26

Last Posted Date: 2024-03-28

Lead Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Target Recruit Count: 30

Registration Number: NCT06226766

Locations: 🇦🇺
Scientia Clinical Research, Randwick, New South Wales, Australia

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Phase 3

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Capecitabine tablets
Drug: JSKN003
Drug: Gemcitabine hydrochloride for injection
Drug: Vinorelbine tartrate injection
Drug: Paclitaxel for injection (albumin-bound type)
Drug: Docetaxel injection
Drug: Eribulin mesylate injection

First Posted Date: 2023-10-12

Last Posted Date: 2023-10-12

Lead Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Target Recruit Count: 400

Registration Number: NCT06079983

Locations: 🇨🇳
Jilin Provincial Cancer Hospital, Changchun, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, China
🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

and more 47 locations

Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: JSKN003

First Posted Date: 2023-02-27

Last Posted Date: 2024-12-30

Lead Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Target Recruit Count: 725

Registration Number: NCT05744427

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
🇨🇳
Sun Yat-sen University Cancer Prevention Center, Guangzhou, China

and more 31 locations

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Advanced Non-small Cell Lung Cancer

Interventions: Biological: KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)
Combination Product: Axitinib

First Posted Date: 2022-06-15

Last Posted Date: 2024-05-01

Lead Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Target Recruit Count: 54

Registration Number: NCT05420220

Locations: 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Yantai Yuhuangding Hospital, Yantai, Shandong, China
🇨🇳
Linyi Cancer Hospital, Linyi, Shandong, China

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy